Brunei Darussalam
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.013 (0.012–0.013) 3 (2.9–3.1)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.27 (0.082–0.57) 65 (20–136)
Incidence  (includes HIV+TB) 0.24 (0.21–0.28) 58 (51–66)
Incidence (HIV+TB only)        
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.68 (0.02–3.8) 0 (0–46)
MDR-TB cases among notified pulmonary
TB cases
1 (0–6) 0 (0–3)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 149   6
Pulmonary, clinically diagnosed 9   0
Extrapulmonary 48   0
       
Total new and relapse 212    
Previously treated, excluding relapses 0    
Total cases notified 212    
Among 212 new and relapse cases:
4 (2%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 159 (107%) 6 (100%) 165
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 212 (100)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB 5  
HIV-positive people provided with IPT 0  
Treatment success rate (%)
New and relapse cases registered in 2012 71
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 50
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 12.2
Drug susceptibility testing (per 5 million population) 12.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-04 Data: www.who.int/tb/data